Article Text
Statistics from Altmetric.com
The advent and increased use of targeted therapies in rheumatology have stimulated the establishment of clinical drug registers. Such registers have evaluated a broad spectrum of outcomes in patients exposed to these uniquely designed, potent and expensive drugs.1–8 Although the main focus of most drug registers in rheumatology is drug safety, other important issues include drug usage, real-life effectiveness and economic consequences.
Results from biologics registers have come to play an important role in the evaluation of safety, effectiveness and treatment strategies, contributing significantly to the evidence base that guides clinical practice and shapes policy decisions. It is thus vital that the underlying studies are carefully conducted, analysed and transparently reported. This ensures (a proper appraisal of) the …
Footnotes
-
Contributors All authors have equally contributed in the discussions about the concept of the work. JZ has written the manuscript, WGD and JA have critically reviewed the manuscript, and all three authors have agreed to authorship.
-
Competing interests None.
-
Provenance and peer review Not commissioned; externally peer reviewed.